Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Breast 1

Conditions

Glioblastoma 2Gliosarcoma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 31Magnetic Resonance Spectroscopy 31Specimen Handling 18Radiation 13Radiotherapy 12Biopsy 11Bevacizumab 11Nivolumab 9X-Rays 7Radiosurgery 7Nuclear Medicine Department, Hospital 7Carboplatin 7Lomustine 6Cyclophosphamide 6Vincristine 5Phantoms, Imaging 5Cisplatin 5ulixertinib 4trametinib 4pembrolizumab 4erdafitinib 4binimetinib 4abemaciclib 4Irinotecan 4Ipilimumab 4Immunoglobulin G 4Etoposide 4Disulfides 4Aminolevulinic Acid 4AZD 6244 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
veliparib × CNS × 30 days × Clear all
NCT02152982 2026-06-03

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03581292 2026-05-27

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 13 charts
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡